Maxim starts Anebulo at Buy on acute cannabis intoxication opportunity

As previously reported, Maxim initiated coverage of Anebulo Pharmaceuticals – which is developing ANEB-001 as an acute cannabis intoxication, or ACI, reversal agent – with a Buy rating and $6 price target. While “rarely fatal,” ACI represents “a significant cause of emergency department visits,” says the analyst, who sees a significant unmet need for ACI with a growing opportunity driven by favorable industry trends. The analyst, who notes that ANEB-001 is currently in an ongoing Phase 2 study, does not believe “the opportunity is fully captured at the current market cap.”